Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (2453)	1/3/2001 11:44:13 PM
From: BulbaMan	Respond to of 52153

Peter: Thanks for your thoughts. And, of course, you're correct that nothing certain about Axiom's valuation can be stated based just on the info from the Cadus 10K. However, given the time periods involved, I think it's a good bet Cadus got about the same deal (percentage-wise) for their money as JAFCO. Anyway, since Cadus is now selling for less than half of cash, it's still a pretty weird situation, even with a zero valuation for Axiom. I recently told the Cadus story to a hedge fund manager I know and he expressed a bit of interest in making an offer for the BMY Cadus stake -- if the market settles down I'm hoping he'll follow up.